## Francois Dabis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3168678/publications.pdf

Version: 2024-02-01

470 papers

28,239 citations

80 h-index 147 g-index

479 all docs

479 docs citations

times ranked

479

17125 citing authors

#	Article	IF	CITATIONS
1	In utero exposure to antiretroviral drugs and pregnancy outcomes: Analysis of the French ANRS pharmacovigilance database. British Journal of Clinical Pharmacology, 2022, 88, 942-964.	2.4	3
2	Early HIV treatment and survival over six years of observation in the ANRS 12249 Treatment as Prevention Trial. HIV Medicine, 2022, , .	2.2	2
3	HIV-1 Evolutionary Dynamics under Nonsuppressive Antiretroviral Therapy. MBio, 2022, 13, e0026922.	4.1	5
4	Costs and economies of scale in repeated home-based HIV counselling and testing: Evidence from the ANRS 12249 Treatment as Prevention trial in South Africa. Social Science and Medicine, 2022, 305, 115068.	3.8	1
5	Barriers influencing task-shifting for the management of depression in people living with HIV: a study from West Africa leDEA cohort collaboration. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2021, 33, 352-356.	1.2	4
6	Atherosclerotic Cardiovascular Events in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus. Clinical Infectious Diseases, 2021, 72, e215-e223.	5.8	6
7	Human papilloma viruses infection among adolescent females perinatally infected with HIV in Côte d'Ivoire. Sexually Transmitted Infections, 2021, 97, 238-243.	1.9	2
8	Early ART Initiation Improves HIV Status Disclosure and Social Support in People Living with HIV, Linked to Care Within a Universal Test and Treat Program in Rural South Africa (ANRS 12249 TasP Trial). AIDS and Behavior, 2021, 25, 1306-1322.	2.7	6
9	The case for an HIV cure and how to get there. Lancet HIV,the, 2021, 8, e51-e58.	4.7	46
10	Cerebral alterations in West African HIV and non-HIV adults aged ≥50: An MRI study. International Journal of Infectious Diseases, 2021, 103, 457-463.	3.3	6
11	Eliminating postnatal HIV transmission in high incidence areas: need for complementary biomedical interventions. Lancet, The, 2021, 397, 1316-1324.	13.7	22
12	Tenâ€year attrition and antiretroviral therapy response among HIVâ€positive adults: a sexâ€based cohort analysis from eight West African countries. Journal of the International AIDS Society, 2021, 24, e25723.	3.0	10
13	Chronic viral hepatitis, <scp>HIV</scp> infection and <scp>Nonâ€Hodgkin</scp> lymphomas in West Africa, a caseâ€control study. International Journal of Cancer, 2021, 149, 1536-1543.	5.1	3
14	Eliminating HIV transmission through breast milk from women taking antiretroviral drugs. BMJ, The, 2021, 374, n1697.	6.0	5
15	Fitting a vaccine into the HIV prevention landscape. Journal of the International AIDS Society, 2021, 24, e25792.	3.0	3
16	Assessment of dietary diversity and nutritional support for children living with HIV in the IeDEA pediatric West African cohort: a non-comparative, feasibility study. BMC Nutrition, 2021, 7, 83.	1.6	1
17	PMTCT care cascade and factors associated with attrition in the first four years after Option B+ implementation in Mozambique. Tropical Medicine and International Health, 2020, 25, 222-235.	2.3	9
18	Assessing the psychometric properties of the French WHOQOL-HIV BREF within the ANRS CO3 Aquitaine Cohort's QuAliV ancillary study. Health and Quality of Life Outcomes, 2020, 18, 220.	2.4	6

#	Article	IF	Citations
19	Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d'Ivoire West Africa. PLoS ONE, 2020, 15, e0236642.	2.5	1
20	Prevalence and factors associated with severe depressive symptoms in older west African people living with HIV. BMC Psychiatry, 2020, 20, 442.	2.6	9
21	International epidemiology databases to evaluate AIDS (IeDEA) in sub-Saharan Africa, 2012–2019. BMJ Open, 2020, 10, e035246.	1.9	63
22	Incidence of Tuberculosis During the First Year of Antiretroviral Treatment in West African HIV-Infected Adults. Open Forum Infectious Diseases, 2020, 7, ofaa203.	0.9	1
23	What do the Universal Test and Treat trials tell us about the path to HIV epidemic control?. Journal of the International AIDS Society, 2020, 23, e25455.	3.0	96
24	Prevalence and factors associated with physical function limitation in older West African people living with HIV. PLoS ONE, 2020, 15, e0240906.	2.5	6
25	Title is missing!. , 2020, 15, e0240906.		0
26	Title is missing!. , 2020, 15, e0240906.		0
27	Title is missing!. , 2020, 15, e0240906.		0
28	Title is missing!. , 2020, 15, e0240906.		0
29	Title is missing!. , 2020, 15, e0240906.		0
30	Title is missing!. , 2020, 15, e0240906.		0
31	Assessment of the scaleâ€up of cervical cancer screening in Abidjan stratified by <scp>HIV</scp> status. International Journal of Gynecology and Obstetrics, 2019, 147, 246-251.	2.3	9
32	Diagnosis and clinical outcomes of extrapulmonary tuberculosis in antiretroviral therapy programmes in lowâ€and middleâ€income countries: a multicohort study. Journal of the International AIDS Society, 2019, 22, e25392.	3.0	24
33	Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study. PLoS ONE, 2019, 14, e0211286.	2.5	8
34	Low incidence of acute rejection within 6 months of kidney transplantation in HIVâ€infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE trial. HIV Medicine, 2019, 20, 202-213.	2.2	7
35	Are European HIV cohort data within EuroCoord representative of the diagnosed HIV population?. Aids, 2019, 33, 133-143.	2.2	20
36	Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies. Journal of Hepatology, 2019, 71, 274-280.	3.7	31

#	Article	IF	CITATIONS
37	Temporal trends of population viral suppression in the context of Universal Test and Treat: the ANRS 12249 TasP trial in rural South Africa. Journal of the International AIDS Society, 2019, 22, e25402.	3.0	7
38	Retention in Care Trajectories of HIV-Positive Individuals Participating in a Universal Test-and-Treat Program in Rural South Africa (ANRS 12249 TasP Trial). Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 375-385.	2.1	30
39	No effect of test and treat on sexual behaviours at population level in rural South Africa. Aids, 2019, 33, 709-722.	2.2	3
40	Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Coâ€infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or Endâ€Stage Liver Disease as Compared to HCV Monoâ€infected Patients. Hepatology, 2019, 70, 939-954.	7.3	28
41	Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART. Journal of Antimicrobial Chemotherapy, 2019, 74, 473-479.	3.0	15
42	Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial. Clinical Infectious Diseases, 2019, 69, 207-214.	5 <b>.</b> 8	48
43	Web-Based Module for the Collection of Electronic Patient-Reported Outcomes in People Living With HIV in Nouvelle Aquitaine, France: Usability Evaluation. JMIR Formative Research, 2019, 3, e15013.	1.4	2
44	Gender differences in the use of cardiovascular interventions in ⟨scp⟩HIV⟨/scp⟩â€positive persons; the D:A:D Study. Journal of the International AIDS Society, 2018, 21, e25083.	3.0	10
45	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. Clinical Infectious Diseases, 2018, 66, 893-903.	5.8	105
46	Retention and mortality on antiretroviral therapy in subâ€Saharan Africa: collaborative analyses of HIV treatment programmes. Journal of the International AIDS Society, 2018, 21, e25084.	3.0	91
47	Optimal breastfeeding durations for HIVâ€exposed infants: the impact of maternal <scp>ART</scp> use, infant mortality and replacement feeding risk. Journal of the International AIDS Society, 2018, 21, e25107.	3.0	10
48	Etiology of hepatocellular carcinoma in <scp>W</scp> est <scp>A</scp> frica, a case–control study. International Journal of Cancer, 2018, 143, 869-877.	5.1	12
49	Comparative assessment of five trials of universal <scp>HIV</scp> testing and treatment in subâ€Saharan Africa. Journal of the International AIDS Society, 2018, 21, e25048.	3.0	81
50	Increased nonâ€ <scp>AIDS</scp> mortality among persons with <scp>AIDS</scp> â€defining events after antiretroviral therapy initiation. Journal of the International AIDS Society, 2018, 21, e25031.	3.0	38
51	Contribution of Maternal Antiretroviral Therapy and Breastfeeding to 24-Month Survival in Human Immunodeficiency Virus-Exposed Uninfected Children: An Individual Pooled Analysis of African and Asian Studies. Clinical Infectious Diseases, 2018, 66, 1668-1677.	<b>5.</b> 8	28
52	Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV,the, 2018, 5, e116-e125.	4.7	187
53	Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. Lancet HIV,the, 2018, 5, e291-e300.	4.7	155
54	Prevalence of hepatitis C among HIV-1, HIV-2 and dually reactive patients: A multi-country cross-sectional survey in West Africa. Journal of Public Health in Africa, 2018, 9, 871.	0.4	2

#	Article	IF	CITATIONS
55	Aging with HIV: what effect on mortality and loss to follow-up in the course of antiretroviral therapy? The IeDEA West Africa Cohort Collaboration. HIV/AIDS - Research and Palliative Care, 2018, Volume 10, 239-252.	0.8	9
56	Preface. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, S1-S2.	2.1	1
57	"lf you are here at the clinic, you do not know how many people need help in the communityâ€. Perspectives of home-based HIV services from health care workers in rural KwaZulu-Natal, South Africa in the era of universal test-and-treat. PLoS ONE, 2018, 13, e0202473.	2.5	5
58	High prevalence of binge drinking among people living with HIV in four African countries. Journal of the International AIDS Society, 2018, 21, e25202.	3.0	26
59	The impact of population dynamics on the population <scp>HIV</scp> care cascade: results from the <scp>ANRS</scp> 12249 Treatment as Prevention trial in rural KwaZuluâ€Natal (South Africa). Journal of the International AIDS Society, 2018, 21, e25128.	3.0	34
60	Universal test and treat is not associated with subâ€optimal antiretroviral therapy adherence in rural South Africa: the ANRS 12249 TasP trial. Journal of the International AIDS Society, 2018, 21, e25112.	3.0	34
61	HIV treatment eligibility expansion and timely antiretroviral treatment initiation following enrollment in HIV care: A metaregression analysis of programmatic data from 22 countries. PLoS Medicine, 2018, 15, e1002534.	8.4	38
62	Integrating Electronic Patient-Reported Outcome Measures into Routine HIV Care and the ANRS CO3 Aquitaine Cohort's Data Capture and Visualization System (QuAliV): Protocol for a Formative Research Study. JMIR Research Protocols, 2018, 7, e147.	1.0	11
63	Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients. World Journal of Hepatology, 2018, 10, 856-866.	2.0	10
64	Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. International Journal of Epidemiology, 2017, 46, dyw211.	1.9	22
65	No significant effect of cannabis use on the count and percentage of circulating CD4 Tâ€cells in HIVâ€HCV coâ€infected patients (ANRS CO13â€HEPAVIH French cohort). Drug and Alcohol Review, 2017, 36, 227-238.	2.1	18
66	Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients – French ANRS CO13 HEPAVIH cohort. Journal of Hepatology, 2017, 67, 23-31.	3.7	45
67	High prevalence of dental caries among HIVâ€infected children in <scp>W</scp> est <scp>A</scp> frica compared to uninfected siblings. Journal of Public Health Dentistry, 2017, 77, 234-243.	1.2	14
68	Physical function, grip strength and frailty in people living with ⟨scp⟩HIV⟨/scp⟩ in subâ€Saharan Africa: systematic review. Tropical Medicine and International Health, 2017, 22, 516-525.	2.3	20
69	Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. Lancet HIV,the, 2017, 4, e251-e259.	4.7	10
70	Smoking status and HIV in low-income and middle-income countries. The Lancet Global Health, 2017, 5, e557-e558.	6.3	5
71	Absence of Decline of Kidney Function in Human Immunodeficiency Virus-Infected Patients Under Routine Clinical Management. Nephron, 2017, 136, 211-220.	1.8	2
72	Hepatitis B treatment eligibility in West Africa: Uncertainties and need for prospective cohort studies. Liver International, 2017, 37, 1116-1121.	3.9	23

#	Article	IF	CITATIONS
73	Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 97-107.	2.1	29
74	Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients. Journal of Hepatology, 2017, 67, 1157-1167.	3.7	25
75	Alcohol use, viral hepatitis and liver fibrosis among HIVâ€positive persons in West Africa: a crossâ€sectional study. Journal of the International AIDS Society, 2017, 20, 21424.	3.0	33
76	We still need to beat HIV. Science, 2017, 357, 335-335.	12.6	8
77	Serum suppression of tumorigenicity 2 level is an independent predictor of all-cause mortality in HIV-infected patients. Aids, 2017, 31, 2355-2365.	2.2	4
78	Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 311-318.	2.1	12
79	CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virusâ€"Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). Clinical Infectious Diseases, 2017, 65, 959-966.	5.8	75
80	Couples HIV counselling and couple relationships in India, Georgia and the Dominican Republic. BMC Public Health, 2017, 17, 901.	2.9	5
81	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. Journal of Antimicrobial Chemotherapy, 2017, 72, 2869-2878.	3.0	17
82	Prevalence and factors associated with depression in people living with HIV in sub-Saharan Africa: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0181960.	2.5	162
83	Implementing universal HIV treatment in a high HIV prevalence and rural South African setting – Field experiences and recommendations of health care providers. PLoS ONE, 2017, 12, e0186883.	2.5	14
84	Updating vital status by tracking in the community among patients with epidemic Kaposi sarcoma who are lost to follow-up in sub-Saharan Africa. BMC Cancer, 2017, 17, 611.	2.6	10
85	Prevalence of hepatitis B and delta according to HIV-type: a multi-country cross-sectional survey in West Africa. BMC Infectious Diseases, 2017, 17, 466.	2.9	17
86	Trends in hepatitis B virus testing practices and management in HIV clinics across sub-Saharan Africa. BMC Infectious Diseases, 2017, 17, 706.	2.9	31
87	Virological Outcomes of Second-line Protease Inhibitor–Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis. Clinical Infectious Diseases, 2017, 64, 1006-1016.	5.8	37
88	Prevention and Care of Hepatitis B in Senegal; Awareness and Attitudes of Medical Practitioners. American Journal of Tropical Medicine and Hygiene, 2017, 97, 389-395.	1.4	16
89	Short article: Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH). European Journal of Gastroenterology and Hepatology, 2017, 29, 786-791.	1.6	4
90	Incidence of Severe Neutropenia in HIV-Infected People Starting Antiretroviral Therapy in West Africa. PLoS ONE, 2017, 12, e0170753.	2.5	14

#	Article	IF	CITATIONS
91	Immunologic response in treatmentâ€naÃ⁻ve HIVâ€2â€infected patients: the IeDEA West Africa cohort. Journal of the International AIDS Society, 2016, 19, 20044.	3.0	13
92	Access to HIV care in the context of universal test and treat: challenges within the ANRS 12249 TasP cluster†and domized trial in rural South Africa. Journal of the International AIDS Society, 2016, 19, 20913.	3.0	62
93	HIV infection, viral hepatitis and liver fibrosis among prison inmates in West Africa. BMC Infectious Diseases, 2016, 16, 249.	2.9	33
94	Incidence and Risk Factors for Severe Bacterial Infections in People Living with HIV. ANRS CO3 Aquitaine Cohort, 2000–2012. PLoS ONE, 2016, 11, e0152970.	2.5	20
95	Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. Aids, 2016, 30, 1731-1743.	2.2	50
96	Short article: Fatigue in the long term after HCV treatment in HIV–HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort). European Journal of Gastroenterology and Hepatology, 2016, 28, 1003-1007.	1.6	7
97	Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals. Aids, 2016, 30, 1583-1596.	2.2	10
98	A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virusâ€coinfected patients. Hepatology, 2016, 64, 1462-1472.	7.3	15
99	Effect of sex and age on outcomes among HIV-2-infected patients starting antiretroviral therapy in West Africa. Aids, 2016, 30, 2707-2714.	2.2	18
100	Network for strong, national, public health institutes in west Africa. Lancet, The, 2016, 387, 2196-2197.	13.7	12
101	When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 214-221.	2.1	22
102	Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. Open Forum Infectious Diseases, 2016, 3, ofw009.	0.9	20
103	Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. Clinical Infectious Diseases, 2016, 62, 1571-1577.	5.8	52
104	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. Clinical Infectious Diseases, 2016, 63, ciw519.	5.8	20
105	Factors associated with antiretroviral treatment initiation amongst HIV-positive individuals linked to care within a universal test and treat programme: early findings of the ANRS 12249 TasP trial in rural South Africa. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 39-51.	1.2	47
106	Longitudinal Analysis of the Associations between Antiretroviral Therapy, Viraemia and Immunosuppression with Lipid Levels: The D:A:D Study. Antiviral Therapy, 2016, 21, 495-506.	1.0	20
107	Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes. Medicine (United States), 2016, 95, e5133.	1.0	3
108	Pitfalls of practicing cancer epidemiology in resource-limited settings: the case of survival and loss to follow-up after a diagnosis of Kaposi's sarcoma in five countries across sub-Saharan Africa. BMC Cancer, 2016, 16, 65.	2.6	25

#	Article	IF	Citations
109	All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus–coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13–HEPAVIH Cohort. Clinical Infectious Diseases, 2016, 63, 763-770.	5.8	52
110	Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. BMC Medicine, 2016, 14, 61.	5.5	100
111	Mortality and survival patterns of people living with HIV-2. Current Opinion in HIV and AIDS, 2016, 11, 537-544.	3.8	32
112	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. Journal of Antimicrobial Chemotherapy, 2016, 71, 1352-1360.	3.0	4
113	Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. International Journal of Epidemiology, 2016, 45, 2038-2049.	1.9	43
114	Uptake of Home-Based HIV Testing, Linkage to Care, and Community Attitudes about ART in Rural KwaZulu-Natal, South Africa: Descriptive Results from the First Phase of the ANRS 12249 TasP Cluster-Randomised Trial. PLoS Medicine, 2016, 13, e1002107.	8.4	135
115	Determinants of Weight Evolution Among HIV-Positive Patients Initiating Antiretroviral Treatment in Low-Resource Settings. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 146-154.	2.1	15
116	Oral health and HIV infection among female sex workers in Abidjan, Côte d'Ivoire. BMC Oral Health, 2015, 15, 154.	2.3	15
117	Triple therapy with boceprevir or telaprevir in a <scp>E</scp> uropean cohort of cirrhotic <scp>HIV</scp> / <scp>HCV</scp> genotype 1â€coinfected patients. Liver International, 2015, 35, 2090-2099.	3.9	10
118	Change of treatment guidelines and evolution of ART initiation in rural South Africa: data of a large HIV care and treatment programme. BMC Infectious Diseases, 2015, 15, 452.	2.9	19
119	Impact of the Ebola epidemic on general and HIV care in Macenta, Forest Guinea, 2014. Aids, 2015, 29, 1883-1887.	2.2	39
120	Implementation and Operational Research. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, e5-e9.	2.1	13
121	Plasma HIV-2 RNA According to CD4 Count Strata among HIV-2-Infected Adults in the IeDEA West Africa Collaboration. PLoS ONE, 2015, 10, e0129886.	2.5	21
122	Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012–2014. Open Forum Infectious Diseases, 2015, 2, ofv018.	0.9	17
123	Boosted Lopinavir– Versus Boosted Atazanavir–Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. Clinical Infectious Diseases, 2015, 60, 1262-1268.	5.8	6
124	Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. Lancet HIV,the, 2015, 2, e335-e343.	4.7	52
125	Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis. Lancet HIV, the, 2015, 2, e271-e278.	4.7	98
126	Severe morbidity after antiretroviral (ART) initiation: active surveillance in HIV care programs, the leDEA West Africa collaboration. BMC Infectious Diseases, 2015, 15, 176.	2.9	2

#	Article	IF	CITATIONS
127	Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH). Clinical Infectious Diseases, 2015, 61, 40-48.	5.8	21
128	Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. Aids, 2015, 29, 221-229.	2.2	208
129	Diabetes and cognitive decline in a French cohort of patients infected with HIV-1. Neurology, 2015, 85, 1065-1073.	1.1	23
130	Burden of <scp>HIV</scp> and hepatitis C coâ€infection: the changing epidemiology of hepatitis C in <scp>HIV</scp> â€infected patients in France. Liver International, 2015, 35, 65-70.	3.9	26
131	Retention in care prior to antiretroviral treatment eligibility in sub-Saharan Africa: a systematic review of the literature. BMJ Open, 2015, 5, e006927.	1.9	28
132	Cancer and HIV infection in referral hospitals from four West African countries. Cancer Epidemiology, 2015, 39, 1060-1065.	1.9	25
133	Tuberculosis in Pediatric Antiretroviral Therapy Programs in Low- and Middle-Income Countries: Diagnosis and Screening Practices. Journal of the Pediatric Infectious Diseases Society, 2015, 4, 30-38.	1.3	14
134	Impact of HCV Treatment and Depressive Symptoms on Adherence to Haart among HIV–HCV-Coinfected Patients: Results from the Anrs-Co13-Hepavih Cohort. Antiviral Therapy, 2014, 19, 171-178.	1.0	11
135	Risk Factors for Cervical Intraepithelial Neoplasia in HIV-Infected Women on Antiretroviral Treatment in CÃ'te d'Ivoire, West Africa. PLoS ONE, 2014, 9, e90625.	2.5	11
136	Reâ€ŧesting and misclassification of HIVâ€⊋ and HIVâ€1&2 dually reactive patients among the HIVâ€⊋ coho of The West African Database to evaluate AIDS collaboration. Journal of the International AIDS Society, 2014, 17, 19064.	ort 3.0	25
137	Gender differences in HIV-positive persons in use of cardiovascular disease-related interventions: D:A:D study. Journal of the International AIDS Society, 2014, 17, 19516.	3.0	17
138	Disease patterns and causes of death of hospitalized HIVâ€positive adults in West Africa: a multicountry survey in the antiretroviral treatment era. Journal of the International AIDS Society, 2014, 17, 18797.	3.0	50
139	Antiretroviral treatment response of HIVâ€infected children after prevention of motherâ€toâ€child transmission in West Africa. Journal of the International AIDS Society, 2014, 17, 18737.	3.0	2
140	Immunodeficiency at the Start of Combination Antiretroviral Therapy in Low-, Middle-, and High-Income Countries. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, e8-e16.	2.1	142
141	Mortality in Patients with HIV-1 Infection Starting Antiretroviral Therapy in South Africa, Europe, or North America: A Collaborative Analysis of Prospective Studies. PLoS Medicine, 2014, 11, e1001718.	8.4	100
142	The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study. CMAJ Open, 2014, 2, E318-E329.	2.4	16
143	Using patient-reported outcomes to improve the management of co-infection with HIV and HCV: the ANRS CO13 HEPAVIH cohort. Expert Review of Gastroenterology and Hepatology, 2014, 8, 351-358.	3.0	5
144	Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). International Journal of Epidemiology, 2014, 43, 691-702.	1.9	64

#	Article	IF	Citations
145	HIV Ascertainment through Repeat Home-based Testing in the Context of a Treatment as Prevention Trial (ANRS 12249 TasP) in Rural South Africa. AIDS Research and Human Retroviruses, 2014, 30, A287-A287.	1.1	5
146	Continuum in <scp>HIV</scp> care from entry to <scp>ART</scp> initiation in rural <scp>K</scp> wa <scp>Z</scp> uluâ€ <scp>N</scp> atal, <scp>S</scp> outh <scp>A</scp> frica. Tropical Medicine and International Health, 2014, 19, 680-689.	2.3	35
147	Individualizing the WHO HIV and infant feeding guidelines. Aids, 2014, 28, S287-S299.	2.2	7
148	Correlates of HIV sustained viral suppression in HIV/hepatitis C virus coinfected patients. Aids, 2014, 28, 1155-1160.	2.2	6
149	Genotypic resistance profiles of HIV-2-treated patients in West Africa. Aids, 2014, 28, 1161-1169.	2.2	43
150	Decline in locomotor functions over time in HIV-infected patients. Aids, 2014, 28, 1441-1449.	2.2	42
151	Incidence of Pregnancy After Antiretroviral Therapy Initiation and Associated Factors in 8 West African Countries. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, e45-e54.	2.1	13
152	High Levels of Alcohol Consumption Increase the Risk of Advanced Hepatic Fibrosis in HIV/Hepatitis C Virus-Coinfected Patients: A Sex-Based Analysis Using Transient Elastography at Enrollment in the HEPAVIH ANRS CO13 Cohort. Clinical Infectious Diseases, 2014, 59, 1190-1192.	5.8	15
153	HIV Prevention in Clinical Care Settings. JAMA - Journal of the American Medical Association, 2014, 312, 390.	7.4	109
154	Factors Associated with HIV Testing History among Pregnant Women and Their Partners in Georgia: The ANRS 12127 Prenahtest Trial. AIDS Research and Treatment, 2014, 2014, 1-6.	0.7	4
155	Delayed HIV diagnosis and initiation of antiretroviral therapy. Aids, 2014, 28, 2297-2306.	2.2	39
156	Modified renal function in pregnancy: impact on emtricitabine pharmacokinetics. British Journal of Clinical Pharmacology, 2014, 78, 1378-1386.	2.4	9
157	Evaluation of the impact of a breast cancer awareness program in rural Ghana: A crossâ€sectional survey. International Journal of Cancer, 2014, 134, 913-924.	5.1	44
158	Oral lesions among <scp>HIV</scp> â€infected children on antiretroviral treatment in <scp>W</scp> est <scp>A</scp> frica. Tropical Medicine and International Health, 2014, 19, 246-255.	2.3	24
159	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clinical Infectious Diseases, 2014, 58, 1312-1321.	5 <b>.</b> 8	140
160	Antiretroviral therapy response among HIV-2 infected patients: a systematic review. BMC Infectious Diseases, 2014, 14, 461.	2.9	36
161	AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000–2008: hospital-based cohort studies. BMC Infectious Diseases, 2014, 14, 278.	2.9	27
162	Cervical cancer prevention in reproductive health services: knowledge, attitudes and practices of midwives in Cà te d'Ivoire, West Africa. BMC Health Services Research, 2014, 14, 165.	2.2	29

#	Article	IF	Citations
163	Test and treat all as soon as possible. The Lancet Global Health, 2014, 2, e2-e3.	6.3	5
164	Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: Results from the ANRS CO13 HEPAVIH cohort study. Journal of Hepatology, 2014, 60, 46-53.	3.7	19
165	Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology, 2014, 83, 134-141.	1.1	112
166	Intimate partner sexual and physical violence among women in Togo, West Africa: Prevalence, associated factors, and the specific role of HIV infection. Global Health Action, 2014, 7, 23456.	1.9	39
167	Handgrip Strength Is Only Weakly Correlated With Physical Function in Well-Controlled HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, e25-e27.	2.1	3
168	The Impact of the 2013 WHO Antiretroviral Therapy Guidelines on the Feasibility of HIV Population Prevention Trials. HIV Clinical Trials, 2014, 15, 185-198.	2.0	6
169	Prevalence and Evolution of Low Frequency HIV Drug Resistance Mutations Detected by Ultra Deep Sequencing in Patients Experiencing First Line Antiretroviral Therapy Failure. PLoS ONE, 2014, 9, e86771.	2.5	42
170	Severe Morbidity According to Sex in the Era of Combined Antiretroviral Therapy: The ANRS CO3 Aquitaine Cohort. PLoS ONE, 2014, 9, e102671.	2.5	11
171	Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial. Trials, 2013, 14. 230.	1.6	105
172	Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. Aids, 2013, 27, 407-415.	2.2	89
173	Discussion on the effect of age on immunological response in the first year of antiretroviral therapy in HIV-1-infected adults. Aids, 2013, 27, 146-147.	2.2	0
174	Insurability of HIV-positive people treated with antiretroviral therapy in Europe. Aids, 2013, 27, 1641-1655.	2.2	11
175	Health Care Resource Utilization in Untreated HIV-Infected Children in A Pediatric Programme, Abidjan, CÃ'te d'Ivoire, 2004–2009. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, e14-e21.	2.1	3
176	Associations between immune depression and cardiovascular events in HIV infection. Aids, 2013, 27, 2735-2748.	2.2	51
177	Chronic Viral Hepatitis Is Associated With Low Bone Mineral Density in HIV-Infected Patients, ANRS CO 3 Aquitaine Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 430-435.	2.1	9
178	Effect of Cytomegalovirus-Induced Immune Response, Self Antigen–Induced Immune Response, and Microbial Translocation on Chronic Immune Activation in Successfully Treated HIV Type 1–Infected Patients: The ANRS CO3 Aquitaine Cohort. Journal of Infectious Diseases, 2013, 207, 622-627.	4.0	61
179	Cost-effectiveness of World Health Organization 2010 Guidelines for Prevention of Mother-to-Child HIV Transmission in Zimbabwe. Clinical Infectious Diseases, 2013, 56, 430-446.	5.8	47
180	Public sector services for the prevention of mother-to-child transmission of HIV infection: a micro-costing survey in Namibia and Rwanda. Bulletin of the World Health Organization, 2013, 91, 407-415.	3.3	10

#	Article	IF	Citations
181	Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Medicine, 2013, 10, e1001510.	8.4	256
182	Measuring Coverage in MNCH: Population HIV-Free Survival among Children under Two Years of Age in Four African Countries. PLoS Medicine, 2013, 10, e1001424.	8.4	24
183	Predictors of CD4+ T-Cell Counts of HIV Type 1–Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. Journal of Infectious Diseases, 2013, 207, 759-767.	4.0	7
184	Editorial Commentary: Turning the Tide on HIV in Women and Children: Preventing Breast-Milk HIV Transmission While Increasing Maternal Life Expectancy. Clinical Infectious Diseases, 2013, 56, 140-142.	5.8	1
185	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥200 Cells/µL in the Post–Combination Antiretroviral Therapy Era. Clinical Infectious Diseases, 2013, 57, 1038-1047.	5.8	92
186	Selfâ€reported alcohol abuse in <scp>HIV</scp> â€" <scp>HCV</scp> coâ€infected patients: a better predictor of <scp>HIV</scp> virological rebound than physician's perceptions ( <scp>HEPAVIH ARNS CO</scp> 13) Tj ETQo	q0 <b>0.0</b> rgB	Γ/ <b>Φν</b> erlock 1
187	Influence of Geographical Origin and Ethnicity on Mortality in Patients on Antiretroviral Therapy in Canada, Europe, and the United States. Clinical Infectious Diseases, 2013, 56, 1800-1809.	5.8	28
188	Dried cervical spots for human papillomaviruses identification. Journal of Medical Virology, 2013, 85, 1222-1228.	5.0	3
189	Outcomes of Antiretroviral Therapy in Children in Asia and Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 208-219.	2.1	81
190	Prevalence of Mycoplasma genitalium Among HIV-Infected Women, Agence Nationale de Recherches sur le SIDA et les hépatites virales CO3 Aquitaine Cohort, France. Sexually Transmitted Diseases, 2013, 40, 653-654.	1.7	2
191	Cognitive disorders in HIV-infected patients. Aids, 2013, 27, 391-400.	2.2	125
192	Association Between ALT Level and the Rate of Cardio/Cerebrovascular Events in HIV-Positive Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 456-463.	2.1	13
193	Increasing HIV testing among male partners. Aids, 2013, 27, 1167-1177.	2.2	47
194	Antiretroviral treatment and quality of life in Africans living with HIV: 12â€month followâ€up in Burkina Faso. Journal of the International AIDS Society, 2013, 16, 18867.	3.0	33
195	Characteristics of HIV-2 and HIV-1/HIV-2 Dually Seropositive Adults in West Africa Presenting for Care and Antiretroviral Therapy: The leDEA-West Africa HIV-2 Cohort Study. PLoS ONE, 2013, 8, e66135.	2.5	32
196	What Will It Take to Eliminate Pediatric HIV? Reaching WHO Target Rates of Mother-to-Child HIV Transmission in Zimbabwe: A Model-Based Analysis. PLoS Medicine, 2012, 9, e1001156.	8.4	53
197	Cohort Profile: The international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. International Journal of Epidemiology, 2012, 41, 1256-1264.	1.9	224
198	Interventions to improve the performance of HIV health systems for treatment-as-prevention in sub-Saharan Africa. Current Opinion in HIV and AIDS, 2012, 7, 140-150.	3.8	27

#	Article	IF	Citations
199	All-cause mortality in treated HIV-infected adults with CD4 >=500/mm3 compared with the general population: evidence from a large European observational cohort collaborationÂ. International Journal of Epidemiology, 2012, 41, 433-445.	1.9	217
200	Altered Vaginal Microbiota Are Associated With Perinatal Mother-to-Child Transmission of HIV in African Women From Burkina Faso. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 299-306.	2.1	42
201	Effect of age on immunological response in the first year of antiretroviral therapy in HIV-1-infected adults in West Africa. Aids, 2012, 26, 951-957.	2.2	36
202	Antiretroviral Therapy and Sustained Virological Response to HCV Therapy are Associated with Slower Liver Fibrosis Progression in HIV–HCV-Coinfected Patients: Study from the Anrs Co 13 Hepavih Cohort. Antiviral Therapy, 2012, 17, 1335-1343.	1.0	25
203	Effect of Hepatitis C Treatment on Cd4 <sup>+</sup> T-C El L Counts And The Risk Of Death In HIVâ€"HCV-Coinfected Patients: The Cohere Collaboration. Antiviral Therapy, 2012, 17, 1541-1550.	1.0	7
204	When should therapy begin for children infected with HIV?. Lancet Infectious Diseases, The, 2012, 12, 900-902.	9.1	2
205	Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: Results from ANRS CO13 HEPAVIH. Journal of Hepatology, 2012, 56, 862-868.	3.7	38
206	Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings. BMC Infectious Diseases, 2012, 12, 147.	2.9	7
207	Children Who Acquire HIV Infection Perinatally Are at Higher Risk of Early Death than Those Acquiring Infection through Breastmilk: A Meta-Analysis. PLoS ONE, 2012, 7, e28510.	2.5	98
208	HIV Status Disclosure and Retention in Care in HIV-Infected Adolescents on Antiretroviral Therapy (ART) in West Africa. PLoS ONE, 2012, 7, e33690.	2.5	94
209	The Spectrum of Cancers in West Africa: Associations with Human Immunodeficiency Virus. PLoS ONE, 2012, 7, e48108.	2.5	43
210	HIV-1 Tropism and Liver Fibrosis in HIV–HCV Co-Infected Patients. PLoS ONE, 2012, 7, e50289.	2.5	4
211	Feasibility and acceptability of rapid HIV screening in a labour ward in Togo. Journal of the International AIDS Society, 2012, 15, 17380.	3.0	12
212	Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus–HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users. Addiction, 2012, 107, 152-159.	3.3	16
213	Hepatitis C virus RNA quantitation in a nationwide French cohort of patients co-infected with HIV and HCV: Should the same test be applied to all samples?. Journal of Virological Methods, 2012, 181, 131-133.	2.1	2
214	Cervical cancer screening by visual inspection in CÃ te d'Ivoire, operational and clinical aspects according to HIV status. BMC Public Health, 2012, 12, 237.	2.9	58
215	Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France). BMC Health Services Research, 2012, 12, 59.	2.2	9
216	Health Facility Characteristics and Their Relationship to Coverage of PMTCT of HIV Services across Four African Countries: The PEARL Study. PLoS ONE, 2012, 7, e29823.	2.5	37

#	Article	IF	CITATIONS
217	CMV plasma DNAemia and risk of cancer among HIV-infected patients: A case–control study nested in the ANRS CO3 Aquitaine Cohort, France, 2002–2007. Journal of Clinical Virology, 2011, 50, 177-180.	3.1	0
218	HIV-induced immune deficiency is associated with a higher risk of hepatocarcinoma, ANRS CO3 Aquitaine Cohort, France, 1998–2008. Journal of Hepatology, 2011, 55, 1058-1062.	3.7	19
219	WHO 2010 Guidelines for Prevention of Mother-to-Child HIV Transmission in Zimbabwe: Modeling Clinical Outcomes in Infants and Mothers. PLoS ONE, 2011, 6, e20224.	2.5	41
220	Pregnancy Outcomes in Women Exposed to Efavirenz and Nevirapine: An Appraisal of the leDEA West Africa and ANRS Databases, Abidjan, CÃ te d'Ivoire. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 183-187.	2.1	79
221	Implementation and Operational Research in Francophone Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, S1-S2.	2.1	2
222	High frequency of poor locomotor performance in HIV-infected patients. Aids, 2011, 25, 797-805.	2.2	65
223	Nevirapine for the Prevention of Mother-to-Child Transmission of HIV: A Nation-Wide Coverage Survey in CÃ te d'Ivoire. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, S3-S8.	2.1	10
224	Severe morbidity and mortality in untreated HIV-infected children in a paediatric care programme in Abidjan, CÃ te d'Ivoire, 2004-2009. BMC Infectious Diseases, 2011, 11, 182.	2.9	34
225	12-month mortality and loss-to-program in antiretroviral-treated children: The leDEA pediatric West African Database to evaluate AIDS (pWADA), 2000-2008. BMC Public Health, 2011, 11, 519.	2.9	52
226	Coverage of intermittent prevention treatment with sulphadoxine-pyrimethamine among pregnant women and congenital malaria in CÃ'te d'Ivoire. Malaria Journal, 2011, 10, 105.	2.3	22
227	Pharmacovigilance for antiretroviral drugs in Africa: lessons from a study in Abidjan, Cote d'Ivoire. Pharmacoepidemiology and Drug Safety, 2011, 20, 1303-1310.	1.9	16
228	Concentrations of Tenofovir and Emtricitabine in Breast Milk of HIV-1-Infected Women in Abidjan, Coì,te d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrobial Agents and Chemotherapy, 2011, 55, 1315-1317.	3.2	118
229	Net survival of perinatally and postnatally HIV-infected children: a pooled analysis of individual data from sub-Saharan Africa. International Journal of Epidemiology, 2011, 40, 385-396.	1.9	135
230	Very High Concentrations of Active Intracellular Phosphorylated Emtricitabine in Neonates (ANRS) Tj ETQq0 0 0	rgBT /Ove	rlock 10 Tf 50
231	Information That Should Be Given to HIV Cohort Participants during Ongoing Research: The Viewpoints of Patient Representatives and Research Professionals. Journal of Empirical Research on Human Research Ethics, 2011, 6, 76-83.	1.3	4
232	Population Pharmacokinetics of Nevirapine in HIV-1-Infected Pregnant Women and Their Neonates. Antimicrobial Agents and Chemotherapy, 2011, 55, 331-337.	3.2	45
233	Plasma and Intracellular Tenofovir Pharmacokinetics in the Neonate (ANRS 12109 Trial, Step 2). Antimicrobial Agents and Chemotherapy, 2011, 55, 2961-2967.	3.2	38
234	Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney International, 2011, 80, 302-309.	5.2	92

#	Article	IF	CITATIONS
235	First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration. Aids, 2010, 24, 1043-1050.	2.2	31
236	Determinants of Smoking Cessation Attempts Among HIV-Infected Patients: Results from a Hospital-Based Prospective Cohort. Current HIV Research, 2010, 8, 212-217.	0.5	11
237	Universal antiretroviral therapy among pregnant and postpartum HIV-infected women would improve maternal health and decrease postnatal HIV transmission. Aids, 2010, 24, 1239-1241.	2.2	8
238	HBV or HCV Coinfections and Risk of Myocardial Infarction in HIV-Infected Individuals: The D:A:D Cohort Study. Antiviral Therapy, 2010, 15, 1077-1086.	1.0	35
239	Couple-oriented prenatal HIV counseling for HIV primary prevention: an acceptability study. BMC Public Health, 2010, 10, 197.	2.9	58
240	To what extent could performance-based schemes help increase the effectiveness of prevention of mother-to-child transmission of HIV (PMTCT) programs in resource-limited settings? a summary of the published evidence. BMC Public Health, 2010, 10, 702.	2.9	19
241	Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, CÃ te d'Ivoire. BMC Infectious Diseases, 2010, 10, 188.	2.9	27
242	The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13) Tj ETQq0 0 0 rgE	BT /Oyerloo	ck 19 Tf 50 46
243	Immunological response to highly active antiretroviral therapy following treatment for prevention of mother to child transmission of HIVâ€1: a study in CÃ'te d'Ivoire. Journal of the International AIDS Society, 2010, 13, 28-28.	3.0	3
244	Risk behaviors in volunteer blood donors who seroconverted for HIV, Abidjan, Côte d'Ivoire 1997 to 2005. Transfusion, 2010, 50, 888-893.	1.6	7
245	Alcohol use and nonâ€adherence to antiretroviral therapy in HIVâ€infected patients in West Africa. Addiction, 2010, 105, 1416-1421.	<b>3.</b> 3	51
246	Mortality after failure of antiretroviral therapy in subâ€Saharan Africa. Tropical Medicine and International Health, 2010, 15, 251-258.	2.3	71
247	Low retention of HIVâ€infected patients on antiretroviral therapy in 11 clinical centres in West Africa. Tropical Medicine and International Health, 2010, 15, 34-42.	2.3	80
248	The Challenge of AIDS-Related Malignancies in Sub-Saharan Africa. PLoS ONE, 2010, 5, e8621.	2.5	88
249	Bacterial Pneumonia among HIV-Infected Patients: Decreased Risk After Tobacco Smoking Cessation. ANRS CO3 Aquitaine Cohort, 2000–2007. PLoS ONE, 2010, 5, e8896.	2.5	49
250	Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Antiâ EHIV Drugs (D:A:D) Study. Journal of Infectious Diseases, 2010, 201, 318-330.	4.0	575
251	Mortality Associated With Discordant Responses to Antiretroviral Therapy in Resource-Constrained Settings. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 70-77.	2.1	38
252	Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy. Sexually Transmitted Infections, 2010, 86, ii28-ii34.	1.9	24

#	Article	IF	Citations
253	Coverage of Nevirapine-Based Services to Prevent Mother-to-Child HIV Transmission in 4 African Countries. JAMA - Journal of the American Medical Association, 2010, 304, 293.	7.4	131
254	Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet, The, 2010, 376, 449-457.	13.7	203
255	HIV drugs for treatment, and for prevention. Lancet, The, 2010, 375, 2056-2057.	13.7	21
256	Maternal and nenonatal tenofovir and emtricitabine to prevent vertical transmission of HIV-1: tolerance and resistance. Aids, 2010, 24, 2481-2488.	2.2	14
257	Effectiveness of Multidrug Antiretroviral Regimens to Prevent Mother-to-Child Transmission of HIV-1 in Routine Public Health Services in Cameroon. PLoS ONE, 2010, 5, e10411.	2.5	22
258	The Financial Burden of Morbidity in HIV-Infected Adults on Antiretroviral Therapy in CÃ'te d'Ivoire. PLoS ONE, 2010, 5, e11213.	2.5	38
259	Evaluation of Three Sampling Methods to Monitor Outcomes of Antiretroviral Treatment Programmes in Low- and Middle-Income Countries. PLoS ONE, 2010, 5, e13899.	2.5	13
260	Difference in Absolute CD4+ Count According to CD4 Percentage between Asian and Caucasian HIV-Infected Patients. Journal of AIDS & Clinical Research, 2010, 01, 1-4.	0.5	27
261	Duration, Pattern of Breastfeeding and Postnatal Transmission of HIV: Pooled Analysis of Individual Data from West and South African Cohorts. PLoS ONE, 2009, 4, e7397.	2.5	61
262	Universal Antiretroviral Therapy for Pregnant and Breastâ€Feeding HIVâ€1–Infected Women: Towards the Elimination of Motherâ€toâ€Child Transmission of HIVâ€1 in Resourceâ€Limited Settings. Clinical Infectious Diseases, 2009, 49, 1936-1945.	5.8	80
263	Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1. Aids, 2009, 23, 825-833.	2.2	29
264	Cost-Effectiveness of Preventing Loss to Follow-up in HIV Treatment Programs: A Côte d'Ivoire Appraisal. PLoS Medicine, 2009, 6, e1000173.	8.4	66
265	Mortality of HIV-Infected Patients Starting Antiretroviral Therapy in Sub-Saharan Africa: Comparison with HIV-Unrelated Mortality. PLoS Medicine, 2009, 6, e1000066.	8.4	161
266	Population Pharmacokinetics of Emtricitabine in Human Immunodeficiency Virus Type 1-Infected Pregnant Women and Their Neonates. Antimicrobial Agents and Chemotherapy, 2009, 53, 1067-1073.	3.2	61
267	Role of Uncontrolled HIV RNA Level and Immunodeficiency in the Occurrence of Malignancy in HIVâ€Infected Patients during the Combination Antiretroviral Therapy Era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clinical Infectious Diseases, 2009, 49, 1109-1116.	5.8	100
268	Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort. Journal of Antimicrobial Chemotherapy, 2009, 63, 1251-1255.	3.0	33
269	Diabetes Mellitus, Preexisting Coronary Heart Disease, and the Risk of Subsequent Coronary Heart Disease Events in Patients Infected With Human Immunodeficiency Virus. Circulation, 2009, 119, 805-811.	1.6	88
270	Beneficial Effects of Offering Prenatal HIV Counselling and Testing on Developing a HIV Preventive Attitude among Couples. Abidjan, 2002–2005. AIDS and Behavior, 2009, 13, 348-355.	2.7	44

#	Article	IF	Citations
271	Tobacco smoking and chewing as risk factors for multiple human papillomavirus infections and cervical squamous intraepithelial lesions in two countries (Côte d'lvoire and Finland) with different tobacco exposure. Cancer Causes and Control, 2009, 20, 163-170.	1.8	24
272	Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Tropical Medicine and International Health, 2009, 14, 1220-1225.	2.3	78
273	Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet, The, 2009, 373, 1352-1363.	13.7	676
274	Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. Aids, 2009, 23, 1867-1874.	2.2	136
275	Antiretroviral therapy in resourceâ€imited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in subâ€saharan Africa, Asia and Latin America. Tropical Medicine and International Health, 2008, 13, 870-879.	2.3	162
276	Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy. BMC Medical Research Methodology, 2008, 8, 68.	3.1	4
277	18-month occurrence of severe events among early diagnosed HIV-infected children before antiretroviral therapy in Abidjan, CÃ te d'Ivoire: A cohort study. BMC Public Health, 2008, 8, 169.	2.9	10
278	Participation of traditional birth attendants in prevention of mother-to-child transmission of HIV services in two rural districts in Zimbabwe: a feasibility study. BMC Public Health, 2008, 8, 401.	2.9	28
279	Tolerance and viral resistance after single-dose nevirapine (NVP) and short-course of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) to prevent mother-to-child transmission (PMTCT) of HIV-1: the TEmAA ANRS 12109 phase II trial, step 1. Retrovirology, 2008, 5, O20.	2.0	4
280	Early mixed feeding and breastfeeding beyond 6 months increase the risk of postnatal HIV transmission: ANRS 1201/1202 Ditrame Plus, Abidjan, CÃ te d'Ivoire. Preventive Medicine, 2008, 47, 27-33.	3.4	59
281	Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet, The, 2008, 371, 1417-1426.	13.7	809
282	Maternal 12-Month Response to Antiretroviral Therapy following Prevention of Mother-to-Child Transmission of HIV Type 1, Ivory Coast, 2003- 2006. Clinical Infectious Diseases, 2008, 46, 611-621.	5.8	43
283	Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. Aids, 2008, 22, 1417-1423.	2.2	92
284	Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. Aids, 2008, 22, 395-402.	2.2	188
285	Validation and Comparison of Simple Noninvasive Indexes for Predicting Liver Fibrosis in HIV-HCV-Coinfected Patients: ANRS CO3 Aquitaine Cohort. American Journal of Gastroenterology, 2008, 103, 1973-1980.	0.4	63
286	Eearly loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bulletin of the World Health Organization, 2008, 86, 559-567.	3.3	275
287	Monitoring effectiveness of programmes to prevent mother-to-child HIV transmission in lower-income countries. Bulletin of the World Health Organization, 2008, 86, 57-62.	3.3	112
288	Cohort Profile: The Paediatric Antiretroviral Treatment Programmes in Lower-Income Countries (KIDS-ART-LINC) Collaboration. International Journal of Epidemiology, 2008, 37, 474-480.	1.9	30

#	Article	IF	CITATIONS
289	Gender and the Use of Antiretroviral Treatment in Resource-Constrained Settings: Findings from a Multicenter Collaboration. Journal of Women's Health, 2008, 17, 47-55.	3.3	178
290	Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. Aids, 2008, 22, 457-468.	2.2	80
291	Children and HIV/AIDS: from research to policy and action in resource-limited settings. Aids, 2008, 22, 797-805.	2.2	41
292	Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, CÃ te d'Ivoire. Aids, 2008, 22, 1815-1820.	2.2	110
293	Rapid scaling-up of antiretroviral therapy in 10 000 adults in CÃ'te d'Ivoire: 2-year outcomes and determinants. Aids, 2008, 22, 873-882.	2.2	168
294	Does short-term virologic failure translate to clinical events in antiretroviral-na $\tilde{A}$ -ve patients initiating antiretroviral therapy in clinical practice?. Aids, 2008, 22, 2481-2492.	2.2	18
295	Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. Aids, 2008, 22, 2291-2302.	2.2	152
296	Response to combination antiretroviral therapy: variation by age. Aids, 2008, 22, 1463-1473.	2.2	188
297	Prophylactic antiretroviral regimens for prevention of mother-to-child transmission of HIV in resource-limited settings. Current Opinion in HIV and AIDS, 2008, 3, 161-165.	3.8	15
298	18-Month Effectiveness of Short-Course Antiretroviral Regimens Combined with Alternatives to Breastfeeding to Prevent HIV Mother-to-Child Transmission. PLoS ONE, 2008, 3, e1645.	2.5	36
299	Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antiviral Therapy, 2008, 13, 959-67.	1.0	50
300	Prognostic Importance of Anaemia in HIV Type-1-Infected Patients Starting Antiretroviral Therapy: Collaborative Analysis of Prospective Cohort Studies. Antiviral Therapy, 2008, 13, 959-967.	1.0	65
301	Variation of CD4 Count and Percentage during Pregnancy and after Delivery: Implications for HAART Initiation in Resource-Limited Settings. AIDS Research and Human Retroviruses, 2007, 23, 1469-1474.	1.1	37
302	Tobacco Addiction and HIV Infection: Toward the Implementation of Cessation Programs. ANRS CO3 Aquitaine Cohort. AIDS Patient Care and STDs, 2007, 21, 458-468.	<b>2.</b> 5	121
303	Two-Year Morbidity–Mortality and Alternatives to Prolonged Breast-Feeding among Children Born to HIV-Infected Mothers in CÑte d'Ivoire. PLoS Medicine, 2007, 4, e17.	8.4	89
304	Do Tests Devised to Detect Recent HIV-1 Infection Provide Reliable Estimates of Incidence in Africa?. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 115-122.	2.1	53
305	Acceptability of Formula-Feeding to Prevent HIV Postnatal Transmission, Abidjan, Côte d'Ivoire. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 77-86.	2.1	30
306	HIV-1 Antiretroviral Drug Resistance in Recently Infected Patients in Abidjan, Côte d'Ivoire: A 4-Year Survey, 2002–2006. AIDS Research and Human Retroviruses, 2007, 23, 1155-1160.	1.1	29

#	Article	IF	CITATIONS
307	Tuberculosis after Initiation of Antiretroviral Therapy in Low-Income and High-Income Countries. Clinical Infectious Diseases, 2007, 45, 1518-1521.	5.8	98
308	Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysisâ€. International Journal of Epidemiology, 2007, 36, 1009-1021.	1.9	207
309	Interpretation of Genotype and Pharmacokinetics for Resistance to Fosamprenavir-Ritonavir-Based Regimens in Antiretroviral-Experienced Patients. Antimicrobial Agents and Chemotherapy, 2007, 51, 1473-1480.	3.2	26
310	Impact of Nevirapine (NVP) Plasma Concentration on Selection of Resistant Virus in Mothers Who Received Single-Dose NVP To Prevent Perinatal Human Immunodeficiency Virus Type 1 Transmission and Persistence of Resistant Virus in Their Infected Children. Antimicrobial Agents and Chemotherapy, 2007, 51, 896-901.	3.2	34
311	Development of resistance after administration of single-dose nevirapine to prevent mother-to-child transmission of HIV. Future HIV Therapy, 2007, 1, 91-101.	0.4	1
312	Virological characterization of an infection with a dual-tropic, multidrug-resistant HIV-1 and further evolution on antiretroviral therapy. Aids, 2007, 21, 103-106.	2.2	10
313	Discordant Responses to Potent Antiretroviral Treatment in Previously Naive HIV-1-Infected Adults Initiating Treatment in Resource-Constrained Countries. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 52-59.	2.1	94
314	Pravastatin in HIV-Infected Patients Treated with Protease Inhibitors: A Placebo-Controlled Randomized Study. HIV Clinical Trials, 2007, 8, 53-60.	2.0	22
315	Prevalence of and Factors Associated With Hepatic Steatosis in Patients Coinfected With Hepatitis C Virus and HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 168-173.	2.1	28
316	Transmission Rates in Consecutive Pregnancies Exposed to Single-Dose Nevirapine in Soweto, South Africa and Abidjan, CÃ'te d'Ivoire. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 206-209.	2.1	29
317	Antiretroviral Treatment and Prevention of Peripartum and Postnatal HIV Transmission in West Africa: Evaluation of a Two-Tiered Approach. PLoS Medicine, 2007, 4, e257.	8.4	118
318	HIV-Infected Adults With a CD4 Cell Count Greater Than 500 Cells/mm3 on Long-Term Combination Antiretroviral Therapy Reach Same Mortality Rates as the General Population. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 72-77.	2.1	348
319	Estimating incidence of HIV infection in childbearing age African women using serial prevalence data from antenatal clinics. Statistics in Medicine, 2007, 26, 320-335.	1.6	18
320	Hepatitis B virus genotypes : a retrospective survey in Southwestern France, 1999-2004. Gastroenterologie Clinique Et Biologique, 2007, 31, 1088-1094.	0.9	18
321	Progression to WHO criteria for starting antiretroviral therapy in a 7-year cohort of adult HIV-1 seroconverters in Abidjan, Cote d'Ivoire. Bulletin of the World Health Organization, 2007, 85, 116-123.	3.3	27
322	Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet, The, 2006, 367, 817-824.	13.7	1,030
323	HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet, The, 2006, 368, 451-458.	13.7	209
324	Vaccines to prevent transmission of HIV-1 via breastmilk: scientific and logistical priorities. Lancet, The, 2006, 368, 511-521.	13.7	33

#	Article	IF	Citations
325	Mortality of HIV-infected patients in low-income countries – Authors' response. Lancet, The, 2006, 368, 2207-2208.	13.7	2
326	Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort. Journal of Clinical Virology, 2006, 36, 95-99.	3.1	6
327	The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. Aids, 2006, 20, 21-28.	2.2	92
328	Acceptability of Routine HIV Testing ("Opt-Out") in Antenatal Services in Two Rural Districts of Zimbabwe. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 514-520.	2.1	119
329	Hepatitis B vaccination in HIV-infected patients: a survey of physicians and patients participating in the Aquitaine cohort. Gastroenterologie Clinique Et Biologique, 2006, 30, 189-195.	0.9	12
330	CD4 Percentages and Total Lymphocyte Counts as Early Surrogate Markers for Pediatric HIV-1 Infection in Resource-Limited Settings. Journal of Tropical Pediatrics, 2006, 52, 346-354.	1.5	14
331	Complementary Feeding Adequacy in Relation to Nutritional Status Among Early Weaned Breastfed Children Who Are Born to HIV-Infected Mothers: ANRS 1201/1202 Ditrame Plus, Abidjan, Col,te d'Ivoire. Pediatrics, 2006, 117, e701-e710.	2.1	49
332	Decrease of human immunodeficiency virus prevalence in antenatal clinics in Abidjan, Côte d'Ivoire, 1995–2002. International Journal of STD and AIDS, 2006, 17, 57-60.	1.1	16
333	Serum Lactate Levels in Infants Exposed Peripartum to Antiretroviral Agents to Prevent Mother-to-Child Transmission of HIV: Agence Nationale de Recherches Sur le SIDA et les Hepatites Virales 1209 Study, Abidjan, Ivory Coast. Pediatrics, 2006, 118, e1071-e1077.	2.1	29
334	Factors Associated with the Occurrence of AIDS-Related Non-Hodgkin Lymphoma in the Era of Highly Active Antiretroviral Therapy: Aquitaine Cohort, France. Clinical Infectious Diseases, 2006, 42, 411-417.	5.8	58
335	Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus. Archives of Internal Medicine, 2006, 166, 1632.	3.8	1,004
336	Low Risk of Nevirapine Resistance Mutations in the Prevention of Motherâ€toâ€Child Transmission of HIVâ€1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Côte d'Ivoire. Journal of Infectious Diseases, 2006, 193, 482-487.	4.0	68
337	Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection. Antiviral Therapy, 2006, 11, 343-50.	1.0	4
338	Change in T-Lymphocyte Count after Initiation of Highly Active Antiretroviral Therapy in HIV-Infected Patients with History of <i>Mycobacterium Avium</i> Complex Infection. Antiviral Therapy, 2006, 11, 343-350.	1.0	9
339	Acceptability of Exclusive Breast-Feeding With Early Cessation to Prevent HIV Transmission Through Breast Milk, ANRS 1201/1202 Ditrame Plus, Abidjan, CÃ te d'Ivoire. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 600-608.	2.1	40
340	Behavior Assessment of Blood Donors Facing the Risk of HIV Infection, Abidjan, Côte D'Ivoire, 2001-2002. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, 618-621.	2.1	3
341	Knowledge, Attitudes, and Beliefs of Health Care Workers Regarding Alternatives to Prolonged Breast-Feeding (ANRS 1201/1202, Ditrame Plus, Abidjan, CÃ te d'Ivoire). Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 102-105.	2.1	11
342	The Changing Incidence of AIDS Events in Patients Receiving Highly Active Antiretroviral Therapy. Archives of Internal Medicine, 2005, 165, 416.	3.8	124

#	Article	IF	Citations
343	A multistate approach for estimating the incidence of human immunodeficiency virus by using data from a prevalent cohort study. Journal of the Royal Statistical Society Series C: Applied Statistics, 2005, 54, 739-752.	1.0	15
344	Avascular Necrosis in HIVâ€Infected Patients: A Caseâ€Control Study from the Aquitaine Cohort, 1997–2002, France. Clinical Infectious Diseases, 2005, 40, 1188-1193.	5.8	26
345	Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. International Journal of Epidemiology, 2005, 34, 979-986.	1.9	72
346	Occult Hepatitis B Virus Infection in HIV-Infected Patients with Isolated Antibodies to Hepatitis B Core Antigen: Aquitaine Cohort, 2002-2003. Clinical Infectious Diseases, 2005, 40, 750-753.	5.8	55
347	Evidence behind the WHO Guidelines: Hospital Care for Children: What Antiretroviral Agents and Regimens are Effective in the Prevention of Mother-to-child Transmission of HIV?. Journal of Tropical Pediatrics, 2005, 52, 235-238.	1.5	3
348	Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America. Clinical Infectious Diseases, 2005, 41, 1772-1782.	5.8	197
349	Transfer and Evaluation of an Automated, Low-Cost Real-Time Reverse Transcription-PCR Test for Diagnosis and Monitoring of Human Immunodeficiency Virus Type 1 Infection in a West African Resource-Limited Setting. Journal of Clinical Microbiology, 2005, 43, 2709-2717.	3.9	221
350	Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa?. Aids, 2005, 19, 1865-1875.	2.2	72
351	Infant Feeding Practices Before Implementing Alternatives to Prolonged Breastfeeding to Reduce HIV Transmission Through Breastmilk in Abidjan, CÃ'te d'Ivoire. Journal of Tropical Pediatrics, 2005, 51, 351-355.	1.5	13
352	Change in atherosclerosis progression in HIV-infected patients: ANRS Aquitaine Cohort, 1999–2004. Aids, 2005, 19, 729-731.	2.2	34
353	Mortality of infants born to HIV-infected mothers in Africa. Lancet, The, 2005, 365, 121-122.	13.7	3
354	Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. Aids, 2005, 19, 309-18.	2.2	143
355	Should nevirapine be used to prevent mother-to-child transmission of HIV among women of unknown serostatus?. Bulletin of the World Health Organization, 2005, 83, 224-8.	3.3	6
356	Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antiviral Therapy, 2005, 10, 811-23.	1.0	43
357	Predictors of Hypertension and Changes of Blood Pressure in HIV-Infected Patients. Antiviral Therapy, 2005, 10, 811-823.	1.0	103
358	Field Evaluation of a Rapid Human Immunodeficiency Virus (HIV) Serial Serologic Testing Algorithm for Diagnosis and Differentiation of HIV Type 1 (HIV-1), HIV-2, and Dual HIV-1-HIV-2 Infections in West African Pregnant Women. Journal of Clinical Microbiology, 2004, 42, 4147-4153.	3.9	63
359	Interaction between HIV-1 and HCV infections: towards a new entity?. Journal of Antimicrobial Chemotherapy, 2004, 53, 936-946.	3.0	24
360	Effect of Perinatal Zidovudine Prophylaxis on the Evolution of Cellâ€Free HIVâ€1 RNA in Breast Milk and on Postnatal Transmission. Journal of Infectious Diseases, 2004, 190, 1422-1428.	4.0	42

#	Article	IF	CITATIONS
361	Late Postnatal Transmission of HIVâ€1 in Breastâ€Fed Children: An Individual Patient Data Metaâ€Analysis. Journal of Infectious Diseases, 2004, 189, 2154-2166.	4.0	442
362	Acceptability and uptake of a package to prevent mother-to-child transmission using rapid HIV testing in Abidjan, ĆÃ te d'Ivoire. Aids, 2004, 18, 697-700.	2.2	46
363	Prevention of mother to child transmission of HIV: evaluation of a pilot programme in a district hospital in rural Zimbabwe. BMJ: British Medical Journal, 2004, 329, 1147-1150.	2.3	80
364	Immune Status and Uptake of Antiretroviral Interventions to Prevent Mother-to-Child Transmission of HIV-1 in Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 755-757.	2.1	6
365	Implementing a rural programme of prevention of mother-to-child transmission of HIV in Zimbabwe: first 18 months of experience. Tropical Medicine and International Health, 2004, 9, 774-783.	2.3	73
366	HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, CÃte d'Ivoire: The ANRS 1236 study. Journal of Medical Virology, 2004, 74, 34-40.	5.0	117
367	Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet, The, 2004, 364, 1236-1243.	13.7	1,026
368	Obtaining informed consent from HIV-infected pregnant women, Abidjan, CÃ te d'Ivoire. Aids, 2004, 18, 1486-1488.	2.2	15
369	Prevention of HIV Transmission Through Breast-feeding: Strengthening the Research Agenda. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 167-168.	2.1	11
370	Use of Antiretroviral Drugs to Prevent HIV-1 Transmission Through Breast-feeding: From Animal Studies to Randomized Clinical Trials. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 178-187.	2.1	93
371	Children and HIV in Africa: what is next?. Lancet, The, 2003, 362, 1597-1598.	13.7	4
372	Estimating the Efficacy of Interventions to Prevent Mother-to-Child Transmission of Human Immunodeficiency Virus in Breastfeeding Populations: Comparing Statistical Methods. American Journal of Epidemiology, 2003, 158, 596-605.	3.4	34
373	Pediatric Viral Human Immunodeficiency Virus Type 1 RNA Levels, Timing of Infection, and Disease Progression in African HIV-1-Infected Children. Pediatrics, 2003, 112, e289-e289.	2.1	65
374	Presence of Key Drug Resistance Mutations in Isolates from Untreated Patients of Abidjan, Côte d'Ivoire: ANRS 1257 Study. AIDS Research and Human Retroviruses, 2003, 19, 713-717.	1,1	34
375	Time-Updated CD4+ T Lymphocyte Count and HIV RNA as Major Markers of Disease Progression in Naive HIV-1-Infected Patients Treated With a Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 380-386.	2.1	18
376	Postnatal transmission of HIV-1 after a maternal short-course zidovudine peripartum regimen in West Africa. Aids, 2003, 17, 1493-1501.	2.2	65
377	Malaria, HIV and pregnancy. Aids, 2003, 17, 275-276.	2.2	14
378	Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Annals of Medicine, 2002, 34, 55-63.	3.8	118

#	Article	IF	CITATIONS
379	Clinical and Biological Evolution of HIV-1 Seroconverters in Abidjan, Côte d'Ivoire, 1997–2000. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 149-157.	2.1	27
380	Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy?. Aids, 2002, 16, 1357-1362.	2.2	56
381	Contraceptive use, protected sexual intercourse and incidence of pregnancies among African HIV-infected women. DITRAME ANRS 049 Project, Abidjan 1995–2000. International Journal of STD and AIDS, 2002, 13, 462-468.	1.1	78
382	Epidemiology of Pertussis in a West African Community before and after Introduction of a Widespread Vaccination Program. American Journal of Epidemiology, 2002, 155, 891-896.	3.4	74
383	Causes and empirical treatment of fever in HIV-infected adult outpatients, Abidjan, Côte d'Ivoire. Aids, 2002, 16, 909-918.	2.2	30
384	Primary HIV-1 infection in African children infected through breastfeeding. Aids, 2002, 16, 2303-2309.	2.2	15
385	Field acceptability and effectiveness of the routine utilization of zidovudine to reduce mother-to-child transmission of HIV-1 in West Africa. Aids, 2002, 16, 2323-2328.	2.2	43
386	Twenty-four month efficacy of a maternal short-course zidovudine regimen to prevent mother-to-child transmission of HIV-1 in West Africa. Aids, 2002, 16, 631-641.	2.2	143
387	HIV-1/AIDS and maternal and child health in Africa. Lancet, The, 2002, 359, 2097-2104.	13.7	217
388	Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet, The, 2002, 360, 119-129.	13.7	1,415
389	Hepatitis B and HIV type 1 co-infection in pregnant African women. Médecine Et Maladies Infectieuses, 2002, 32, 396-397.	5.0	1
390	Short-course antiretroviral treatment may reduce mother-to-child HIV-1 transmission during delivery. Evidence-Based Healthcare and Public Health, 2002, 6, 165-166.	0.0	0
391	Primary HIV-1 drug resistance in Abidjan (Côte d'Ivoire): a genotypic and phenotypic study. Aids, 2002, 16, 488-491.	2.2	26
392	HIV infection, malaria, and pregnancy: a prospective cohort study in Kigali, Rwanda American Journal of Tropical Medicine and Hygiene, 2002, 66, 56-60.	1.4	45
393	Maternal plasma viral load, zidovudine and mother-to-child transmission of HIV-1 in Africa: DITRAME ANRS 049a trial. Aids, 2001, 15, 517-522.	2.2	33
394	Effect of early chemoprophylaxis with co-trimoxazole on nutritional status evolution in HIV-1-infected adults in Abidjan, CÃ te d'Ivoire. Aids, 2001, 15, 869-876.	2.2	15
395	Prognostic Factors of Combined Viral Load and CD4+ Cell Count Responses Under Triple Antiretroviral Therapy, Aquitaine Cohort, 1996–1998. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 161-167.	2.1	12
396	18-Month mortality and perinatal exposure to zidovudine in West Africa. Aids, 2001, 15, 771-779.	2.2	64

#	Article	IF	CITATIONS
397	Weight Loss and Body Mass Index as Predictors of HIV Disease Progression to AIDS in Adults. Aquitaine Cohort, France, 1985–1997. Journal of the American College of Nutrition, 2001, 20, 609-615.	1.8	43
398	Sexual and Reproductive Life of Women Informed of Their HIV Seropositivity: A Prospective Cohort Study in Burkina Faso. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 367-372.	2.1	122
399	Prognostic Factors of Combined Viral Load and CD4+ Cell Count Responses Under Triple Antiretroviral Therapy, Aquitaine Cohort, 1996–1998. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 161-167.	2.1	33
400	Hepatitis B and C infections, human immunodeficiency virus and other sexually transmitted infections among women of childbearing age in CÃ te d'Ivoire, West Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2001, 95, 493-496.	1.8	30
401	The effect of cotrimoxazole coadministrated with antituberculous drugs on serum transaminases in HIV-infected adults from the Ivory Coast. British Journal of Clinical Pharmacology, 2001, 52, 611-612.	2.4	O
402	Estimating the efficacy of interventions to prevent mother-to-child transmission of HIV in breast-feeding populations: development of a consensus methodology. Statistics in Medicine, 2001, 20, 3539-3556.	1.6	63
403	Early diagnosis of paediatric HIV-1 infection among African breast-fed children using a quantitative plasma HIV RNA assay. Aids, 2001, 15, 1849-1856.	2.2	64
404	Stabilization of HIV infection rates in urban Burkina Faso, 1995–1999. International Journal of STD and AIDS, 2001, 12, 460-462.	1.1	9
405	Incidence of pregnancies among African HIV-infected women, Abidjan, 1995–2000. Aids, 2001, 15, 2327-2330.	2.2	5
406	Sexual and Reproductive Life of Women Informed of Their HIV Seropositivity: A Prospective Cohort Study in Burkina Faso. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 367-372.	2.1	1
407	Dietary Problems in African HIV-1–Infected Adults, Abidjan, Côte d'Ivoire. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 23, 357-358.	2.1	2
408	Preventing mother-to-child transmission of HIV-1 in Africa in the year 2000. Aids, 2000, 14, 1017-1026.	2.2	42
409	Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Aids, 2000, 14, 971-978.	2.2	80
410	Prevention of infectious complications of paediatric HIV infection in Africa. Aids, 2000, 14, 1091-1099.	2.2	13
411	Prognostic factors after non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus. Cancer, 2000, 88, 1696-1702.	4.1	35
412	Lipodystrophy, Metabolic Disorders, and Human Immunodeficiency Virus Infection: Aquitaine Cohort, France, 1999. Clinical Infectious Diseases, 2000, 31, 1482-1487.	5.8	152
413	Atherogen lipid profile in HIV-1-infected patients with lipodystrophy syndrome. European Journal of Internal Medicine, 2000, 11, 257-263.	2.2	15
414	Medical care costs of children born to HIV-infected mothers, in Abidjan, Côte d'Ivoire 1996–1997. Aids, 2000, 14, 1076.	2.2	3

#	Article	IF	Citations
415	Thresholds of CD4 cells for initiating trimethoprim-sulfamethoxazole prophylaxis in west Africa. Aids, 2000, 14, 2628-2629.	2.2	3
416	Maternal vitamin A status and mother-to-child transmission of HIV in West Africa. Aids, 2000, 14, 908.	2.2	1
417	Natural History of Human Immunodefiency Virus Type 1 Infection in Children: A Five-Year Prospective Study in Rwanda. Pediatrics, 1999, 104, e56-e56.	2.1	205
418	Evaluation of 2 techniques of HIV pre-test counselling for pregnant women in West Africa. International Journal of STD and AIDS, 1999, 10, 199-201.	1.1	17
419	HIV Infection among Pregnant Women in Bobo-Dioulasso, Burkina Faso: Comparison of Voluntary and Blinded Seroprevalence Estimates. International Journal of STD and AIDS, 1999, 10, 738-740.	1.1	12
420	Haematological characteristics and HIV status of pregnant women in Abidjan, Côte d'Ivoire, 1995–1996. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999, 93, 419-422.	1.8	20
421	Increase in CD3+ CD4- T lymphocytes in patients with AIDS and disseminated Mycobacterium avium-intracellulare complex infection: a prospective study. Microbes and Infection, 1999, 1, 771-776.	1.9	1
422	Lipodystrophy in HIV-1-infected patients. Lancet, The, 1999, 354, 867-868.	13.7	16
423	6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet, The, 1999, 353, 786-792.	13.7	491
424	Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations Aquitaine Cohort, France, 1996-1998. Aids, 1999, 13, 115-151.	2.2	117
425	Impaired fertility in HIV-1-infected pregnant women: a clinic-based survey in Abidjan, Côte d'Ivoire, 1997. Aids, 1999, 13, 517-521.	2.2	37
426	Cancer incidence in a cohort of human immunodeficiency virus seroconverters., 1998, 82, 996-998.		3
427	Squamous intraepithelial lesions of the cervix, invasive cervical carcinoma, and immunosuppression induced by human immunodeficiency virus in africa. Cancer, 1998, 82, 2401-2408.	4.1	52
428	Human papillomavirus and human immunodeficiency virus infections: relation with cervical dysplasia-neoplasia in African women., 1998, 76, 480-486.		84
429	Late postnatal mother-to-child transmission of HIV-1. Lancet, The, 1998, 352, 1630.	13.7	3
430	Vitamin A supplementation and HIV-1 mother-to-child transmission in Africa. Lancet, The, 1998, 352, 653-654.	13.7	5
431	International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection. Lancet, The, 1998, 352, 597-600.	13.7	238
432	Pregnancy, body weight and human immunodeficiency virus infection in African women: a prospective cohort study in Kigali (Rwanda), 1992- 1994. Pregnancy and HIV Study Group (EGE). International Journal of Epidemiology, 1998, 27, 1072-1077.	1.9	13

#	Article	IF	CITATIONS
433	CD4 count and CD4% in African HIV-infected people. International Journal of Epidemiology, 1998, 27, 928-928.	1.9	2
434	Rapid Change in the Use of Antiretroviral Agents and Improvement in a Population of HIV-Infected Patients: France, 1995 to 1997. Journal of Acquired Immune Deficiency Syndromes, 1998, 18, 358-364.	0.3	42
435	Determinants of delayed diagnosis of HIV infection in France, 1993–1995. Aids, 1998, 12, 795-800.	2.2	59
436	Chorioamnionitis and Pregnancy Outcome in HIV-Infected African Women. Journal of Acquired Immune Deficiency Syndromes, 1998, 18, 293-298.	0.3	34
437	Attitude of pregnant women towards HIV testing in Abidjan, Côte dÊ $^1\!\!/$ Ivoire and Bobo-Dioulasso, Burkina Faso. Aids, 1998, 12, 2337-2344.	2.2	70
438	Cost-effectiveness and cost-benefit in the prevention of mother-to-child transmission of HIV in developing countries. Aids, 1998, 12, 1571-1580.	2.2	30
439	Acceptability of voluntary HIV testing by pregnant women in developing countries. Aids, 1998, 12, 2489-2493.	2.2	100
440	Effect of Gender, Age, Transmission Category, and Antiretroviral Therapy on the Progression of Human Immunodeficiency Virus Infection Using Multistate Markov Models. Epidemiology, 1998, 9, 605-612.	2.7	47
441	Effect of HIV-1 infection on pregnancy outcome in women in Kigali, Rwanda, 1992–1994. Aids, 1998, 12, 643-650.	2.2	91
442	Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. Aids, 1998, 12, 2313-2320.	2.2	61
443	Squamous intraepithelial lesions of the cervix, invasive cervical carcinoma, and immunosuppression induced by human immunodeficiency virus in africa. Cancer, 1998, 82, 2401-2408.	4.1	34
444	REPORT OF A WORKSHOP FOR CLINICAL RESEARCH. Pediatric Infectious Disease Journal, 1998, 17, 581-586.	2.0	63
445	Zidovudine and Breast-Feeding. AIDS Patient Care and STDs, 1997, 11, 4-5.	2.5	5
446	CD4+ T-Lymphocyte Counts in HIV Infection. Journal of Acquired Immune Deficiency Syndromes, 1997, 14, 361-363.	0.3	57
447	Safety of Haemophilus influenzae conjugate vaccine in children born to HIV-1 infected mothers: Kigali (Rwanda), 1992–1994. Vaccine, 1996, 14, 177-178.	3.8	2
448	A cohort study of factors associated with failure to return for HIV post-test counselling in pregnant women. Aids, 1996, 10, 69-76.	2,2	44
449	Increases in CD3+CD4-CDS-T Lymphocytes in AIDS Patients with Disseminated Mycobacterium avium-intracellulare Complex Infection. Journal of Infectious Diseases, 1996, 174, 969-976.	4.0	45
450	Growth of human immunodeficiency type 1-infected and uninfected children: a prospective cohort study in Kigali, Rwanda, 1988 to 1993. Pediatric Infectious Disease Journal, 1996, 15, 479-485.	2.0	83

#	Article	IF	Citations
451	Prospective cohort study of the effect of pregnancy on the progression of human immunodeficiency virus infection. Obstetrics and Gynecology, 1995, 86, 886-891.	2.4	50
452	Surveillance of heterosexually acquired HIV infection and AIDS. Lancet, The, 1995, 346, 308-309.	13.7	4
453	Tuberculosis and chemoprophylaxis in Africa. Lancet, The, 1995, 345, 867-868.	13.7	6
454	Seroincidence of HIV-1 infection in African women of reproductive age. Aids, 1994, 8, 983-986.	2.2	56
455	Herpes Zoster and Human Immunodeficiency Virus Infection: A Cohort Study of 101 Coinfected Patients. Journal of Infectious Diseases, 1993, 168, 245-245.	4.0	30
456	Mother–to–Child Transmission of Human Immunodeficiency Virus Type 1 (HIV–1) and Its Determinants: A Cohort Study in Kigali, Rwanda. American Journal of Epidemiology, 1993, 137, 589-599.	3.4	69
457	Non-Acquired Immune Deficiency Syndrome-Defining Malignancies in a Hospital-Based Cohort of Human Immunodeficiency Virus-Infected Patients: Bordeaux, France, 1985-1991. Journal of the National Cancer Institute, 1992, 84, 1593-1595.	6.3	37
458	Estimating the incubation period of paediatric AIDS in Rwanda. Aids, 1992, 6, 1515-1520.	2.2	26
459	Women and HIV infection. Aids, 1992, 6, 1187-1194.	2.2	32
460	BCG vaccination in children born to HIV-positive mothers. Lancet, The, 1992, 340, 799-800.	13.7	8
461	Postnatal transmission of HIV-1 associated with breast abscess. Lancet, The, 1992, 339, 1490-1491.	13.7	49
462	Perinatal transmission of HIV-1. Aids, 1991, 5, 295-300.	2.2	66
463	Postnatal Transmission of Human Immunodeficiency Virus Type 1 from Mother to Infant. New England Journal of Medicine, 1991, 325, 593-598.	27.0	370
464	Telematics and sentinel health information system with general practitioners in Aquitaine, southwest France. Medical Informatics = Medecine Et Informatique, 1989, 14, 281-286.	0.8	1
465	Evaluation and simplification of the World Health Organization clinical case definition for paediatric AIDS. Aids, 1989, 3, 221-226.	2.2	41
466	Loss of Maternal Measles Antibody during Infancy in an African City. International Journal of Epidemiology, 1989, 18, 264-268.	1.9	40
467	Improper practices for diarrhoea treatment in Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1988, 82, 935-936.	1.8	1
468	THE EPIDEMIOLOGY OF MEASLES IN A PARTIALLY VACCINATED POPULATION IN AN AFRICAN CITY: IMPLICATIONS FOR IMMUNIZATION PROGRAMS. American Journal of Epidemiology, 1988, 127, 171-178.	3.4	43

#	Article	IF	CITATIONS
469	SHJGELLOSIS AT A CARIBBEAN RESORT. American Journal of Epidemiology, 1987, 126, 1173-1180.	3.4	14
470	MEASLES CONTROL IN AFRICA. Lancet, The, 1986, 328, 162-163.	13.7	1